International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지
DOI QR코드

DOI QR Code

Icaritin, a Flavonoid Derived from the Herb Epimedium, Promotes Osteogenic Differentiation of MC3T3-E1 Cells

  • Park, Dan-Bi (Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University) ;
  • Lee, Hee Su (Department of Oral anatomy, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University) ;
  • Ko, Seong-Hee (Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University)
  • Received : 2017.08.31
  • Accepted : 2017.09.16
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Osteoporosis is a metabolic bone disease that is characterized by low bone mass resulting from an increase in bone resorption relative to bone formation. The most current therapies for osteoporosis have focused on inhibiting bone resorption by osteoclasts. The purpose of this study is to develop new anabolic agents for treatment of osteoporosis that have fewer risks compared to conventional therapies. We searched the natural products that were derived from the traditional Asian medicines which have been used for treatment of bone related diseases. Icaritin is a flavonoid glycoside derived from the herb Epimedium which has beneficial effects on bone formation. To determine the effect of icaritin on bone formation, we examined the effect of icaritin on MC3T3-E1 cell proliferation and differentiation. For determining the effects of icaritin on proliferation, we performed the MTT assay using MC3T3-E1 cells. To evaluate whether icaritin could promote the osteogenic differentiation of MC3T3-E1 cells, alkaline phosphatase (ALP) activity and mRNA expressions of Runx2, osteocalcin (OCN), RANKL, and osteoprotegerin (OPG) were determined. Icaritin increased MC3T3-E1 cell proliferation. Icaritin increased the ALP activity of MC3T3-E1 cells on 72 hour culture in osteogenic media. mRNA expression of Runx2 was increased after 24 hour culture with icaritin. mRNA expression of osteocalcin was increased after 72 hour culture with icaritin. In addition, icaritin increased the mRNA expressions of OPG and RANKL. However, icaritin increased the mRNA expression of OPG much more than that of RANKL, and then, it increased the OPG/RANKL ratio. These results suggest that icaritin promotes osteogenic differentiation of osteoblasts and decreases osteoclast formation regulated by osteoblasts.

Keywords

References

  1. Milat F, Ebeling PR. Osteoporosis treatment: a missed opportunity. Med J Aust 2016;205:185-190 https://doi.org/10.5694/mja16.00568
  2. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20. doi: 10.1016/j.amjmed.2012.06.023.
  3. Ma H, He X, Yang Y, Li M, Hao D, Jia Z. The genus Epimedium: an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2011 ;134:519-541. doi:10.1016/j.jep.2011.01.001
  4. Jia M, Nie Y, Cao DP, Xue YY, Wang JS, Zhao L, Rahman K, Zhang QY, Qin LP. Potential Antiosteoporotic Agents from Plants: A Comprehensive Review. Evid Based Complement Alternat Med. 2012; 2012:1-28. doi:10.1155/2012/364604
  5. Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci 2015;126:57-68. http://dx.doi.org/10.1016/j.lfs.2015.01.006
  6. Zhang G, Wang XL, Sheng H, Xie XH, He YX, Yao XS, Li ZR, Lee KM, He W, Leung KS, Qin L. Constitutional flavonoids derived from Epimedium dose-dependently reduce incidence of steroid-associated osteonecrosis not via direct action by themselves on potential cellular targets. PLoS One. 2009; 29:4(7):1-11. doi:10.1371/journal.pone.0006419
  7. Poole KE, Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005;5(6):612-617. doi: 10.1016/j.coph.2005.07.004
  8. Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure RC. Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today. 2014; 19(3):204-208. doi: 10.1016/j.drudis.2013.07.015.
  9. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R,Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, LasserN, Lewis CE, Manson J, Margolis K, Ockene J, O'SullivanMJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, llace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. https://doi.org/10.1001/jama.291.14.1701
  10. Beral V, Million women study collaborators. Breast cancer and hormone- replacement therapy in the million women study. Lancet 2003;362:419-427. https://doi.org/10.1016/S0140-6736(03)14065-2
  11. Hsieh TP, Sheu SY, Sun JS, Chen MH, Liu MH. Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine. 2010;17(6):414-423. doi: 10.1016/j.phymed.2009.08.007.
  12. Mok SK, Chen WF, Lai WP, Leung PC, Wang XL, Yao XS, Wong MS. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptordependent osteoblastic functions in UMR 106 cells. Br J Pharmacol. 2010 ;159(4):939-949. doi: 10.1111/j.1476-5381.2009.00593.x.
  13. Xia L, Li Y, Zhou Z, Dai Y, Liu H, Liu H. Icariin delivery porous PHBV scaffolds for promoting osteoblast expansion in vitro. Mater. Sci. Eng C. 2013;33 :3545-3552. doi: 10.1016/j.msec.2013.04.050.
  14. An Ji, Yang H, Zhang Q, Liu C, Zhao J, Zhang L, Chen B. Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 2016;147:46-58. doi: 10.1016/j.lfs.2016.01.024.
  15. Xiao H-H, Fung C-Y, MokS-K, Wong K-C, Ho M-X, Wang X-L, Yao X-S, Wong M-S. Flavonoids from Herba epimedii selectively activate estrogen receptor alpha ($ER{\alpha}$) and stimulate ER-dependent osteoblastic functions in UMR-106 cells. J Steroid Biochem & Mole Biol. 2014;143:141-151. doi: 10.1016/j.jsbmb.2014.02.019.
  16. Wu Z, Ou L, Wang C, Yang Li, Wang P, Liu H, Xiong Y, Sun K, Zhang R, Zhu X. Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. Biomedicine & Pharmacotherapy 2017;94:1-9. doi: 10.1016/j.biopha.2017.07.071.
  17. Zheng D, Peng S, Yang SH, Shao ZW, Yang C, Feng Y, Wu W, Zhen WX. The beneficial effect of icariin on bone is diminished in osteoprotegerin-deficient mice. Bone 2012;51:85-92. doi: 10.1016/j.bone.2012.04.006.
  18. Hsieh TP, Sheu SY, Sun JS, Chen MH Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/$NF-{\kappa}B$ regulated HIF-$1{\alpha}$ and PGE(2) synthesis. Phytomedicine 2011;18(2-3):176-185. doi: 10.1016/j.phymed.2010.04.003.
  19. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-3602 https://doi.org/10.1073/pnas.95.7.3597
  20. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000;11(11):905-913 https://doi.org/10.1007/s001980070028